**Description:** TD139 is an inhaled galectin-3 inhibitor (Kd: 14 nM).

**Storage:** 2 years -80°C in solvent; 3 years -20°C powder;

<table>
<thead>
<tr>
<th>Solubility</th>
<th>DMSO</th>
<th>5 mg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>Insoluble</td>
<td></td>
</tr>
<tr>
<td>Ethanol</td>
<td>3 mg/mL</td>
<td></td>
</tr>
</tbody>
</table>

(< 1 mg/mL refers to the product slightly soluble or insoluble)

**Receptor (IC50)**

| galectin-3 | 14 nM (Kd) |

**In vitro Activity**
TD139 has a high affinity for galectin-3 with a Kd of 14 nM and 10 nM for galectin-1, but low affinity for galectins 2, 4N, 4C, 7, 8N, or 9N [1].

**In vivo Activity**
In primary lung AECs TD139 reduces TGF-β1–induced β-catenin translocation to the nucleus, with most of the β-catenin remaining at the cell surface. TD139 blocks TGF-β1–induced β-catenin phosphorylation. A marked reduction in fibrosis and β-catenin activation accompanied by the decreased galectin-3 expression is observed in the lungs of WT mice treated with TD139 [1]. Pretreatment of WT C57BL/6 mice with TD139 leads to the attenuation of liver injury and milder infiltration of IFNγ- and IL-17- and -4-producing CD4(+) T cells, as well as an increase in the total number of IL-10-producing CD4(+) T cells and F4/80(+) CD206(+) alternatively activates macrophages and prevents the apoptosis of liver-infiltrating MNCs [2].

**Reference**

**FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**
Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, please follow the storage recommendations on the product data sheet.